Book contents
- High-Risk Pregnancy: Management Options
- High-Risk Pregnancy: Management Options
- Copyright page
- Contents
- Contributors
- Section 1 Prepregnancy Problems
- Section 2 Early Prenatal Problems
- Section 3 Late Prenatal – Fetal Problems
- Section 4 Problems Associated with Infection
- Chapter 24 Hepatitis Virus Infections in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 25 Human Immunodeficiency Virus in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 26 Rubella, Measles, Mumps, Varicella, and Parvovirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 27 Cytomegalovirus, Herpes Simplex Virus, Adenovirus, Coxsackievirus, and Human Papillomavirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 28 Parasitic Infections in Pregnancy (Content last reviewed: 15th June 2018)
- Chapter 29 Other Infectious Conditions in Pregnancy (Content last reviewed: 11th November 2020)
- Section 5 Late Pregnancy – Maternal Problems
- Section 6 Late Prenatal – Obstetric Problems
- Section 7 Postnatal Problems
- Section 8 Normal Values
- Index
- References
Chapter 26 - Rubella, Measles, Mumps, Varicella, and Parvovirus in Pregnancy (Content last reviewed: 11th November 2020)
Published online by Cambridge University Press: 15 November 2017
Book contents
- High-Risk Pregnancy: Management Options
- High-Risk Pregnancy: Management Options
- Copyright page
- Contents
- Contributors
- Section 1 Prepregnancy Problems
- Section 2 Early Prenatal Problems
- Section 3 Late Prenatal – Fetal Problems
- Section 4 Problems Associated with Infection
- Chapter 24 Hepatitis Virus Infections in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 25 Human Immunodeficiency Virus in Pregnancy (Content last reviewed: 23rd July 2019)
- Chapter 26 Rubella, Measles, Mumps, Varicella, and Parvovirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 27 Cytomegalovirus, Herpes Simplex Virus, Adenovirus, Coxsackievirus, and Human Papillomavirus in Pregnancy (Content last reviewed: 11th November 2020)
- Chapter 28 Parasitic Infections in Pregnancy (Content last reviewed: 15th June 2018)
- Chapter 29 Other Infectious Conditions in Pregnancy (Content last reviewed: 11th November 2020)
- Section 5 Late Pregnancy – Maternal Problems
- Section 6 Late Prenatal – Obstetric Problems
- Section 7 Postnatal Problems
- Section 8 Normal Values
- Index
- References
Summary
Rubella (German measles or “third disease”) is an exanthematous disease caused by a single-stranded RNA virus of the togavirus family.
- Type
- Chapter
- Information
- High-Risk PregnancyManagement Options, pp. 644 - 658Publisher: Cambridge University PressFirst published in: 2017
References
Further Reading
Davidkin, I. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20 year follow-up. J Infect Dis 2008; 197: 950–6.
Enders, G, Miller, E, Cradock-Watson, J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343: 1547–50.
Enders, M, Weidner, A, Rosenthal, T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008; 197: 58–62.
Enders, M, Weidner, A, Zoellner, I, Searle, K, Enders, G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24: 513–18.
McQuillan, GM, Kruszon-Moran, D, Hyde, TB, et al. Seroprevalence of measles antibody in the US population, 1999–2004. J Infect Dis 2007; 196: 1459–64.
Siegel, M. Congenital malformations following chickenpox, measles, mumps, and hepatitis: results of a cohort study. JAMA 1993; 226: 1521–4.
Wilson, E, Goss, MA, Marin, M, et al. Varicella vaccine exposure during pregnancy: data from 10 years of the Pregnancy Registry. J Infect Dis 2008; 197 (Suppl 2): S178–84.
References
Gershon, AA. Rubella virus (German measles). In Mandell, GL, Douglas, RG, Bennett, JE (eds), Principles and Practice of Infectious Diseases, 3rd edn. New York, NY: Churchill Livingstone, 1990, pp. 1242–7.
Cochi, SL, Edmonds, LE, Dyer, K, et al. Congenital rubella syndrome in the United States, 1970–1985. Am J Epidemiol 1989; 129: 349–61.
Grossman, JH. Why congenital rubella continues to occur. Contemp Obstet Gynecol 1990; 36: 50–4.
Freij, BJ, South, MA, Sever, JL, et al. Maternal rubella and the congenital rubella syndrome. Clin Perinatol 1988; 15: 247–57.
McIntosh, EDG, Menser, MA. A fifty-year follow-up of congenital rubella. Lancet 1992; 340: 414–15.
Miller, E, Cradock-Watson, JE, Pollock, TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2: 781–4.
Centers for Disease Control and Prevention (CDC). Rubella and congenital rubella syndrome: United States, 1994–1997. MMWR Morb Mortal Wkly Rep 1997; 46: 350–3.
Centers for Disease Control and Prevention (CDC). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013. MMWR Morb Mortal Wkly Rep 2013; 62 (RR-4): 1–34.
Bukasa, A, Campbell, H, Brown, K, et al. Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016. Euro Surveill 2018; 23(19): 17–00381. https://doi.org/10.2807/1560-7917.ES.2018.23.19.17-00381.
Cordier, AG, Vauloup-Fellous, C, Grangeot-Keros, L, et al. Pitfalls in the diagnosis of congenital rubella syndrome in the first trimester of pregnancy. Prenat Diagn 2012; 32: 496–7
Centers for Disease Control and Prevention (CDC). Notice to readers. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50: 1117.
Davidkin, I. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20 year follow-up. J Infect Dis 2008; 197: 950–6.
O’Shea, S, Best, JM, Banatvala, JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983; 148: 639–47.
Enders, G, Calm, A, Shaub, J. Rubella embryopathy after previous maternal rubella vaccination. Infection 1984; 12: 96–8.
Bart, SW, Stetler, HC, Preblud, SR, et al. Fetal risk associated with rubella vaccine: An update. Rev Infect Dis 1985; 7 (Suppl 1): S95–102.
American College of Obstetricians and Gynecologists. Immunization during pregnancy (ACOG Committee Opinion No. 282). Obstet Gynecol 2003; 101: 207–12.
Badilla, X, Morice, A, Avila-Aguero, ML, et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007; 26: 830–5.
Daffos, F, Forestier, F, Grangeot-Keros, L, et al. Prenatal diagnosis of congenital rubella. Lancet 1984; 2: 1–3.
Bosma, TJ, Corbett, KM, O’Shea, S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995; 33: 1075–9.
Ho-Terry, L, Terry, GM, Londesborough, P. Diagnosis of foetal rubella virus infection by polymerase chain reaction. J Gen Virol 1990; 71: 1607–11.
Tanemura, M, Suzumori, K, Yagami, Y, Katow, S. Diagnosis of fetal rubella infection with reverse transcription and nested polymerase chain reaction: a study of 34 cases diagnosed in fetuses. Am J Obstet Gynecol 1996; 174: 578–82.
Modlin, JF. Measles virus. In Belshe, RB (ed.), Human Virology. Littleton, MA: PSG Publishing, 1984, pp. 333–60.
Gavish, D, Kleinman, Y, Morag, A, Chajek-Shaul, T. Hepatitis and jaundice associated with measles in young adults. An analysis of 65 cases. Arch Intern Med 1983; 143: 674–7.
Gershon, AA. Chickenpox, measles and mumps. In Remington, JS, Klein, JO, Wilson, CB, et al. (eds), Infectious Diseases of the Fetus and Newborn Infant, 7th edn. Philadelphia, PA: Elsevier Saunders, 2011, pp. 661–705.
Phadke, VK, Bednarczyk, RA, Salmon, DA, Omer, SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA 2016; 315: 1149–58. https://doi.org/10.1001/jama.2016.1353.
Parker Fiebelkorn, A, Redd, SB, Gallagher, K, et al. Measles in the United States during the postelimination era. J Infect Dis 2010; 202: 1520–8.
Eberhart-Phillips, JE, Frederick, PD, Baron, RC, Mascola, L. Measles in pregnancy: a descriptive study of 58 cases. Obstet Gynecol 1993; 82: 797–801.
Atmar, RL, Englund, JA, Hammill, H. Complications of measles during pregnancy. Clin Infect Dis 1992; 14: 217–26.
Ogbuanu, IU, Zeko, S, Chu, SY, et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009–2010. Clin Infect Dis 2014; 58: 1086–92.
Moroi, K, Saito, S, Durata, T, et al. Fetal death associated with measles virus infection of the placenta. Am J Obstet Gynecol 1991; 164: 107–8.
Stein, SJ, Greenspoon, JS. Rubeola during pregnancy. Obstet Gynecol 1991; 78: 925–9.
de Swart, RL. The pathogenesis of measles revisited. Pediatr Infect Dis J 2008; 27: S84–8.
Korones, SB. Uncommon virus infections of the mother, fetus, and newborn: influenza, mumps, and measles. Clin Perinatal 1988; 15: 259–72.
Siegel, M. Congenital malformations following chickenpox, measles, mumps, and hepatitis: results of a cohort study. JAMA 1993; 226: 1521–4.
Nahmias, AJ, Armstrong, G. Mumps virus and endocardial fibroelastosis. N Engl J Med 1966; 275: 1448–50.
Hersh, BS, Fine, PE, Kent, WK. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119: 187–93.
Centers for Disease Control and Prevention (CDC). Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep 2008; 57: 1103–5.
Whitley, RJ. Varicella-zoster virus. In Mandell, GL, Douglas, RG, Bennett, JE (eds), Principles and Practice of Infectious Diseases, 3rd edn. New York, NY: Churchill Livingstone, 1990, pp. 1153–9.
Pahud, BA, Glaser, CA, Dekker, CL, et al. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis 2011; 203: 316–23.
Harris, RE, Rhoades, ER. Varicella pneumonia complicating pregnancy: report of a case and review of literature. Obstet Gynecol 1965; 25: 734–6.
Harger, JH, Ernest, JM, Thurnau, GR, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002; 185: 422–7.
Haake, DA, Zakowski, PC, Haake, DL, et al. Early treatment for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 12: 788–98.
Smego, RA, Asperilla, MO. Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol 1991; 78: 1112–16.
Balducci, J, Rodis, JR, Rosengren, S, et al. Pregnancy outcome following first-trimester varicella infection. Obstet Gynecol 1992; 79: 5–6.
Pastuszak, AL, Levy, M, Schick, B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330: 901–5.
Paryani, SG, Arvin, AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986; 314: 1542–6.
Enders, G, Miller, E, Cradock-Watson, J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343: 1547–50.
Harger, JH, Ernest, JM, Thurnau, GR, et al. Frequency of congenital varicella syndrome in prospective cohort of 347 pregnant women. Obstet Gynecol 2002; 100: 260–5.
Mattson, SN, Jones, KL, Gramling, LJ, et al. Neurodevelopmental follow-up of children of women infected with varicella during pregnancy: a prospective study. Pediatr Infect Dis J 2003; 22: 809–23.
Meyers, JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis 1974; 129: 215–17.
Cuthbertson, G, Weiner, CP, Giller, RH, et al. Prenatal diagnosis of second trimester congenital varicella syndrome by virus-specific immunoglobulin. J Pediatr 1987; 111: 592–5.
Isada, NB, Paar, DP, Johnson, MP, et al. In utero diagnosis of congenital varicella-zoster virus infection by chorionic villous sampling using polymerase chain reaction. Am J Obstet Gynecol 1991; 165: 1727–30.
Center for Disease Control and Prevention (CDC). Prevention of varicella updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56 (RR-4): 1–40.
Wilson, E, Goss, MA, Marin, M, et al. Varicella vaccine exposure during pregnancy: data from 10 years of the Pregnancy Registry. J Infect Dis 2008; 197 (Suppl 2): S178–84.
Khandaker, G, Marshall, H, Peadon, E, et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011; 96: 453–6.
Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of VariZIG: United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 574–6.
Levin, MJ, Duchon, JM, Swamy, GK, Gershon, AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 2019; 14(7): e0217749. https://doi.org/10.1371/journal.pone.0217749.
Balfour, HH, Kelly, JM, Suarez, CS, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990; 116: 633–9.
Huang, YC, Lin, TY, Lin, YJ, et al. Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr 2001; 160: 91–4.
Serjeant, GR, Topley, JM, Mason, K, et al. Outbreak of aplastic crises in sickle cell anemia associated with parvovirus-like agent. Lancet 1981; 2: 595–7.
Thurn, J. Human parvovirus B19: historical and clinical review. Rev Infect Dis 1988; 10: 1005–11.
Kurtzman, GJ, Ozawa, K, Cohen, B, et al. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317: 287–94.
White, DG, Woolf, AD, Mortimer, PP, et al. Human parvovirus arthropathy. Lancet 1985; 1: 419–21.
Anderson, MJ, Lewis, E, Kidd, IM, et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg 1984; 93: 85–93.
Brown, KE, Anderson, SM, Young, NS. Erythrocyte P antigen: cellular receptor for B19. Science 1993; 262: 114–17.
Young, N, Mortimer, P. Viruses and bone marrow failure. Blood 1984; 63: 729–37.
Morey, AL, Ferguson, DJ, Fleming, KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in-vitro: evidence of cell death by apoptosis. J Pathol 1993; 169: 213–20.
Puccetti, C, Contoli, M, Bonvicini, F, et al. Parvovirus B19 in pregnancy: possible consequences of vertical transmission. Prenat Diagn 2012; 32: 897–902.
Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990; 300: 1166–70.
Gratacos, E, Torres, PJ, Vdal, J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995; 171: 1360–3.
Rodis, JF, Quinn, DL, Gary, W, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990; 163: 1168–71.
Guidozzi, F, Ballot, D, Rothberg, A. Human B19 parvovirus infection in an obstetric population: a prospective study determining fetal outcome. J Reprod Med 1994; 39: 36–8.
Markenson, GR, Yancey, ML. Parvovirus B19 infections in pregnancy. Semin Perinatol 1998; 22: 309–17.
Harger, JH, Adler, SP, Koch, WC, Harger, GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998; 91: 413–20.
Miller, E, Fairley, CK, Cohen, BJ, Seng, C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 174–8.
Enders, M, Weidner, A, Zoellner, I, Searle, K, Enders, G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24: 513–18.
Kinney, J, Anderson, L, Farrar, J, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157: 663–7.
Rodis, JF, Rodner, C, Hansen, AA, et al. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 1998; 91: 125–8.
Dembinsk, J, Haverkamp, F, Maara, H, et al. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19–induced fetal hydrops. BJOG 2002; 109: 1232–4.
De Jong, EP, Lindenburg, IT, van Klink, JM, et al. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. Am J Obstet Gynecol 2012; 206: 204.e1–5.
Koch, WC, Adler, SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8: 83–7.
Woolf, AD, Campion, GV, Chishick, A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149: 1153–6.
Gillespie, SM, Cartter, ML, Asch, S, et al. Occupational risk of human parvovirus B19 infection for school and daycare personnel during an outbreak of erythema infectiosum. JAMA 1990; 263: 2061–5.
Valeur-Jensen, AK, Pedersen, CB, Westergaard, T, et al. Risk factors for parvovirus B19 in pregnancy. JAMA 1999; 281: 1099–105.
Schwarz, TF, Jager, G, Gilch, S. Comparison of seven commercial tests for the detection of parvovirus B19–specific IgM. Zentralbl Bakteriol 1997; 285: 525–30.
Torok, T. Human parvovirus B19. In Remington, J, Klein, J (eds), Infectious Diseases of the Fetus and Newborn Infant. Philadelphia, PA: Saunders, 1995, pp. 668–702.
Rotbart, HA. Human parvovirus infections. Annu Rev Med 1990; 41: 25–34.
Torok, TS, Wang, QY, Gary, GW, et al. Prenatal diagnosis on intrauterine infection with parvovirus B19 by the polymerase chain reaction technique. Clin Infect Dis 1992; 14: 149–55.
Clewley, JP. Polymerase chain reaction assay of parvovirus B19 DNA in clinical specimens. J Clin Microbiol 1989; 27: 2647–51.
Yamakawa, Y, Oka, H, Hori, S, et al. Detection of human parvovirus B19 DNA by nest polymerase chain reaction. Obstet Gynecol 1995; 86: 126–9.
Enders, M, Weidner, A, Rosenthal, T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008; 197: 58–62.
Cosmi, E, Mari, G, Delle-Chiaie, L, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol 2002; 187: 1290–93.
Mielke, G, Enders, G. Late onset of hydrops fetalis following intrauterine parvovirus B19 infection. Fetal Diagn Ther 1997; 12: 40–2.
Fairley, C, Smoleniec, J, Caul, O, Miller, E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335–7.
Schild, RL, Bald, R, Plath, H, et al. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 1999; 13: 161–6.
Sheikh, AU, Ernest, JM, O’Shea, M. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol 1992; 167: 337–41.
Humphrey, W, Magoon, M, O’Shaughnessy, R. Severe nonimmune hydrops secondary to parvovirus B19 infection: spontaneous reversal in-utero and survival of a term infant. Obstet Gynecol 1991; 78: 900–2.